Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Wilfredo F. Garcia-Beltran,Wilfredo F. Garcia-Beltran,Evan C. Lam,Kerri St. Denis,Adam Nitido,Zeidy H. Garcia,Blake M. Hauser,Jared Feldman,Maia N. Pavlovic,David Gregory,Mark C. Poznansky,Alex Sigal,Alex Sigal,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Vivek Naranbhai,Alejandro B. Balazs +17 more
Reads0
Chats0
TLDR
In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2.About:
This article is published in Cell.The article was published on 2021-04-29 and is currently open access. It has received 1109 citations till now. The article focuses on the topics: Vaccination & Humoral immunity.read more
Citations
More filters
Journal ArticleDOI
Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2.
Katherine Laiton-Donato,Carlos Franco-Muñoz,Diego A. Álvarez-Díaz,Hector Alejandro Ruiz-Moreno,José A. Usme-Ciro,Diego Andrés Prada,Jhonnatan Reales-González,Sheryll Corchuelo,María T. Herrera-Sepúlveda,Julian Naizaque,Gerardo Santamaría,Jorge Rivera,Paola Rojas,Juan Hernández Ortiz,Andrés F. Cardona,Diana Malo,Franklin Prieto-Alvarado,Fernando Gómez,Magdalena Wiesner,Martha Lucia Ospina Martínez,Marcela Mercado-Reyes +20 more
TL;DR: In this article, the authors identify the emergence of the B.1.621 lineage, considered a variant of interest (VOI) with the accumulation of several substitutions affecting the Spike protein, including the amino acid changes I95I, Y144T, Y145S and the insertion 146 N in the N-terminal domain, R346K, E484K and N501Y in the Receptor binding Domain (RBD) and P681H in the S1/S2 cleavage site of the Spikeprotein.
Journal ArticleDOI
Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants.
Pengcheng Han,Pengcheng Han,Pengcheng Han,Chao Su,Chao Su,Yanfang Zhang,Chongzhi Bai,Anqi Zheng,Chengpeng Qiao,Qing Wang,Sheng Niu,Sheng Niu,Qian Chen,Qian Chen,Yuqin Zhang,Weiwei Li,Hanyi Liao,Jing Li,Zengyuan Zhang,Heecheol Cho,Mengsu Yang,Xiaoyu Rong,Xiaoyu Rong,Yu Hu,Yu Hu,Niu Huang,Jinghua Yan,Qihui Wang,Xin Zhao,George F. Gao,George F. Gao,Jianxun Qi +31 more
TL;DR: In this paper, the authors examined several SARS-CoV-2 variants of concern (VOCs) including Alpha, Beta, and Gamma, and demonstrated that five variants receptor-binding domain (RBD) increased binding affinity for hACE2, and four variants pseudoviruses increased entry into susceptible cells.
Journal ArticleDOI
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
TL;DR: In this article , the authors conducted a systematic review and meta-analysis to provide a comprehensive overview of the effectiveness profile of COVID-19 vaccines against SARS-CoV-2 variants of concern (VOC).
Journal ArticleDOI
mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants.
Aurélien Sokal,Giovanna Barba-Spaeth,Ignacio Fernández,Matteo Broketa,Imane Azzaoui,Andrea De La Selle,Alexis Vandenberghe,Slim Fourati,Anaïs Roeser,Annalisa Meola,Magali Bouvier-Alias,Etienne Crickx,Laetitia Languille,Marc Michel,Bertrand Godeau,S. Gallien,Giovanna Melica,Yann Nguyen,Virginie Zarrouk,Florence Canoui-Poitrine,Jérôme Mégret,Jean-Michel Pawlotsky,Simon Fillatreau,Pierre Bruhns,Félix A. Rey,Jean-Claude Weill,Claude-Agnès Reynaud,Pascal Chappert,Matthieu Mahévas +28 more
TL;DR: This article studied longitudinal cohorts of naive and disease-recovered individuals for up to 2 months after SARS-CoV-2 mRNA vaccination and assessed the quality of the memory response by analysis of antibody repertoires, affinity, and neutralization against variants of concern (VOCs) using unbiased cultures of 2,452 MBCs.
Journal ArticleDOI
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
Peter G. Kremsner,Rodolfo Andrés Ahuad Guerrero,Eunate Arana-Arri,Gustavo Aroca Martínez,Marc J.M. Bonten,Reynaldo Chandler,Gonzalo Corral,Eddie Jan Louis De Block,Lucie Ecker,Julian J. Gabor,Carlos Alberto Garcia Lopez,Lucy Gonzales,María Angélica Granados González,Nestor Gorini,Martin P. Grobusch,Adrian D Hrabar,Helga Junker,Alan Kimura,Claudio F. Lanata,Claudio F. Lanata,Clara Lehmann,Isabel Leroux-Roels,Philipp Mann,Michel F. Martinez-Resendez,Theresa J. Ochoa,Theresa J. Ochoa,Theresa J. Ochoa,Carlos Alberto Poy,Maria Jose Reyes Fentanes,Luis Maria Rivera Mejia,Vida Veronica Ruiz Herrera,Xavier Sáez-Llorens,Oliver Schönborn-Kellenberger,Mirjam Schunk,Alexandra Sierra Garcia,Itziar Vergara,Thomas Verstraeten,Marisa Vico,Lidia Oostvogels,Luciano Lovesio,Fabián Diez,Franco Grazziani,Maria Cristina Ganaha,Viviana Judith Zalatnik,Ricardo Julio Dittrich,Lidia Espínola,Sandra Lambert,Andrea Longhi,Claudia Vecchio,María Mastruzzo,Alberto Moreno Fernandez,Silvina Borchowiek,Roberto Potito,Fernando Martin Guardiani,Sofia Castella,Monica Foccoli,Aldana Pedernera,Ariel Braida,Virginia Durigan,Carolina Martella,Antonela Bobat,Bruno Emilio Boggia,Sergio Andrés Nemi,Javier Gerardo Tartaglione,Fabián César Piedimonte,Jessie De Bie,Humberto Reynales Londoño,Paula Andrea Rodríguez Ordoñez,Johanna Marcela García Cruz,Leonardo Bautista Toloza,Margot Cecilia Ladino González,Adriana Pilar Zambrano Ochoa,Iñigo Prieto Pradera,Daniela Torres Hernandez,Diana Patricia Mazo Elorza,Maria Fernanda Collazos Lennis,Beatriz Vanegas Dominguez,Lina Marianur Solano Mosquera,Rolf Fendel,Wim Alexander Fleischmann,Erik Koehne,Andrea Kreidenweiss,Carsten Köhler,Meral Esen,Carola Horn,Sandra Eberts,Arne Kroidl,Kristina Huber,Verena Thiel,Sonia Mazara Rosario,Gilda Reyes,Laura Rivera,Yeycy Donastorg,Flavia Lantigua,Dania Torres Almanzar,Rosalba Candelario,Lourdes Peña Mendez,Nadia Rosario Gomez,Antonio Portolés-Pérez,Ana Ascaso del Río,Leonor Laredo Velasco,Maria Jesus Bustinduy Odriozola,Igor Larrea Arranz,Luis Ignacio Martínez Alcorta,María Isabel Durán Laviña,Natale Imaz-Ayo,Susana Meijide,Aitor García-de-Vicuña,Ana Santorcuato,Mikel Gallego,Gloria Mayela Aguirre-García,Jocelyn Olmos Vega,Pablo González Limón,Andrea Vázquez Villar,Jaime Chávez Barón,Felipe Arredondo Saldaña,Juan de Dios Luján Palacios,Laura Julia Camacho Choza,Eduardo Gabriel Vázquez Saldaña,Sandra Janeth Ortega Dominguez,Karen Sofia Vega Orozco,Ivonne Aimee Torres Quiroz,Alejandro Martinez Avendaño,Javier Herrera Sanchez,Esperanza Guzman,Laura Castro Castrezana,Guillermo Miguel Ruiz Palacios y Santos,Ronald Frank Jacobus de Winter,Hanna K de Jonge,Jenny L Schnyder,Wim Boersma,Lisa Hessels,Remco Djamin,Simone van der Sar,Rodrigo DeAntonio,Moisés Peña,Gabriel Rebollon,Marianela Rojas,Johnny Escobar,Bruno Hammerschlag Icaza,Digna Y Wong T,Paulo Barrera Perigault,Sergio Ruiz,Milagros Chan,Dommie Janneth Arias Hoo,Ana I Gil,Carlos R Celis,Maria Pia Balmaceda,Omar Flores,Mayra Ochoa,Bia Peña,Carolina de la Flor,Camille María Webb,Enrique Cornejo,Fatima Sanes,Valerie Mayorga,Gladys Valdiviezo,Suzanne Pamela Ramírez Lamas,Gustavo Alberto Grandez Castillo,Javier R. Lama,Milagros Erika Matta Aguirre,Lesly Angela Arancibia Luna,Óscar Carbajal Paulet,José Zambrano Ortiz,Anais Camara,Fernanda Guzman Quintanilla,Carmen Diaz-Parra,Jose Morales-Oliva,Rubelio E Cornejo,Sheby A Ricalde,Jhonny Vidal,Luis Rios Nogales,Darline Cheatham-Seitz,Giorgia Gregoraci,Alain Brecx,Lisa Walz,Dominik Vahrenhorst,Tobias Seibel,Gianluca Quintini +178 more
TL;DR: The HERALD trial as discussed by the authors is a randomized, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America.
References
More filters
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
Bette T. Korber,Will Fischer,Sandrasegaram Gnanakaran,Hyejin Yoon,James Theiler,Werner Abfalterer,Nick Hengartner,Elena E. Giorgi,Tanmoy Bhattacharya,Brian T. Foley,Kathryn M. Hastie,Matthew Parker,David G Partridge,Cariad Evans,Timothy M. Freeman,Thushan I de Silva,Adrienne Angyal,Rebecca Brown,Laura Carrilero,Luke R. Green,Luke R. Green,Luke R. Green,Danielle C. Groves,Katie Johnson,Alexander J Keeley,Benjamin B Lindsey,Paul J. Parsons,Mohammad Raza,Sarah Rowland-Jones,Nikki Smith,Rachel Tucker,Dennis Wang,Matthew Wyles,Charlene McDanal,Lautaro G. Perez,Haili Tang,Alex Moon-Walker,Alex Moon-Walker,Alex Moon-Walker,Sean P. J. Whelan,Celia C. LaBranche,Erica Ollmann Saphire,David C. Montefiori +42 more
TL;DR: A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic, and it is found that the G614 variant grows to higher titer as pseudotyped virions.
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Journal ArticleDOI
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
Nina Le Bert,Anthony T. Tan,Kamini Kunasegaran,Christine Y.L. Tham,Morteza Hafezi,Adeline Chia,Melissa Hui Yen Chng,Meiyin Lin,Meiyin Lin,Nicole Tan,Martin Linster,Wan Ni Chia,Mark I-Cheng Chen,Lin-Fa Wang,Eng Eong Ooi,Shirin Kalimuddin,Paul A. Tambyah,Jenny G. Low,Jenny G. Low,Yee-Joo Tan,Yee-Joo Tan,Antonio Bertoletti,Antonio Bertoletti +22 more
TL;DR: Infection with betacoronaviruses induces multi-specific and long-lasting T cell immunity against the structural N protein, and SARS-CoV-2-reactive T cells were found in individuals who had recovered from SARS or COVID-19 and in unexposed donors, although with different patterns of immunoreactivity.
Related Papers (5)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Nicholas G Davies,Sam Abbott,Rosanna C. Barnard,Christopher I Jarvis,Adam J. Kucharski,James D Munday,Carl A. B. Pearson,Timothy W Russell,Damien C. Tully,Alex D. Washburne,Tom Wenseleers,Amy Gimma,William Waites,Kerry L. M. Wong,Kevin van Zandvoort,Justin D. Silverman,Karla Diaz-Ordaz,Ruth H. Keogh,Rosalind M Eggo,Sebastian Funk,Mark Jit,Katherine E. Atkins,Katherine E. Atkins,W. John Edmunds +23 more
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
Bette T. Korber,Will Fischer,Sandrasegaram Gnanakaran,Hyejin Yoon,James Theiler,Werner Abfalterer,Nick Hengartner,Elena E. Giorgi,Tanmoy Bhattacharya,Brian T. Foley,Kathryn M. Hastie,Matthew Parker,David G Partridge,Cariad Evans,Timothy M. Freeman,Thushan I de Silva,Adrienne Angyal,Rebecca Brown,Laura Carrilero,Luke R. Green,Luke R. Green,Luke R. Green,Danielle C. Groves,Katie Johnson,Alexander J Keeley,Benjamin B Lindsey,Paul J. Parsons,Mohammad Raza,Sarah Rowland-Jones,Nikki Smith,Rachel Tucker,Dennis Wang,Matthew Wyles,Charlene McDanal,Lautaro G. Perez,Haili Tang,Alex Moon-Walker,Alex Moon-Walker,Alex Moon-Walker,Sean P. J. Whelan,Celia C. LaBranche,Erica Ollmann Saphire,David C. Montefiori +42 more